

## County Durham & Tees Valley Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Thursday 11<sup>th</sup> March 2021**

### Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **○** - Second line / alternative green drug
- A** **Amber Specialist initiation / recommendation drug**. Can be recommended by a specialist for initiation in primary care; or be initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs
- X** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within County Durham & Tees Valley.
- ⊘** **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in County Durham & Tees Valley.
- ▷** **Unclassed Drug** - Drugs that do not fall into one of the above categories

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meetings</b>				
<b>Melatonin modified release, Slenyto®, 1mg, 5mg tablets for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.</b>	✓ <b>ASC</b>			<p>CCG commissioned tariff included drug.</p> <p>Approved at November 2020 APC for licensed indication in children with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome only, as licensed product in this patient group.</p> <p>APC noted due to potential financial implications this has now received final approval from County Durham, Tees Valley, and North Yorkshire CCG Exec Committee.</p> <p>The updated shared care guideline to support this will be finally approved at March 2021 TEWV D&amp;T and then adopted by CCGs/Trusts in the area covered by CD&amp;TV APC.</p>
<b>2) New Requests</b>				
None				
<b>3) New formulations &amp; extensions to use</b>				
None				
<b>4) Products considered by NICE</b>				
<b>TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>TA664: Liraglutide for managing overweight and obesity</b>	✓ <b>R</b>			The formulary will reflect the TAG – CCG is the responsible commissioner.
<b>TA665: Upadacitinib for treating severe rheumatoid arthritis</b>	✓ <b>R</b>			The formulary will reflect the TAG – CCG is the responsible commissioner.
<b>TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA669: Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies</b>	✓ ✗			The formulary will reflect the TAG – NHS England is the responsible commissioner (NICE did not recommend).
<b>TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>5) Appeals against earlier decisions by the APC</b>				
None				
<b>6) Products considered by NTAG</b>				
<b>Solriamfetol for narcolepsy in adults</b>	✓ <b>R</b>			CCG commissioned tariff excluded drug. The formulary will reflect the NTAG recommendation.
<b>Solriamfetol for obstructive sleep apnoea in adults</b>	✓ ✗			CCG commissioned tariff excluded drug. The formulary will reflect the NTAG recommendation.
<b>Teriparatide Biosimilar</b>	✓ <b>R</b>			CCG commissioned tariff excluded drug. The formulary will reflect the NTAG recommendation.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Dupilumab and Omalizumab for chronic rhinosinusitis with nasal polyps	✓ ✗			CCG commissioned tariff excluded drug. The formulary will reflect the NTAG recommendation.
<b>7) Miscellaneous decisions by the APC</b>				
Nebulised Aztreonam lysine (Cayston®) 75 mg powder and solvent for nebuliser solution	✓ R			NHSE commissioned tariff excluded drug. Is recommended for third-line use in the following subpopulation within its licensed indication: for suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older. Request approved by Jan 2021 STHFT D&T. <b>Decision:</b> Add to formulary as RED drug.
Dolutegravir 50mg/ Lamivudine 300mg FDC tablets (Dovato)	✓ R			NHSE commissioned tariff excluded drug. NICE approved for HIV and request approved by Jan 2021 STHFT D&T. <b>Decision:</b> Add to formulary as RED drug.
Dolutegravir 50mg/ Rilpivirine 25mg FDC tablets (Juluca)	✓ R			NHSE commissioned tariff excluded drug. NICE approved for HIV and request approved by Jan 2021 STHFT D&T. <b>Decision:</b> Add to formulary as RED drug.
Phenol In Glycerol 5% W/V Intrathecal Neurolysis for Cancer pain – for palliative nerve block.	✓ R			CCG commissioned tariff included drug. Request from STHFT. Intrathecal chemical neurolysis with Phenol is a neuro-destructive technique to provide saddle anesthesia for perineal/pelvic pain, in patients unresponsive to pharmacological therapy or not amenable to surgical treatment. Its use has been advocated in patients with terminal illness with a short life expectancy of less than a year. <b>Decision:</b> Add to formulary as RED drug
Teriparatide for osteoporosis in men	✓ R			NHSE commissioned tariff excluded drug as long as Trust is commissioned by NHSE as a specialist centre. <b>Decision:</b> Approve for addition to the formulary as per Interim Clinical Commissioning Policy Statement: Teriparatide for Osteoporosis in Men (Adults). NHS England Reference: 201101P
Dapsone for Dermatology Indications	✓ ASC			CCG commissioned tariff included drug. <b>Decision:</b> change from AMBER Specialist Initiation to AMBER Shared Care approved as felt better meets criteria for an AMBER Shared Care drug.

The following guidelines were presented to and approved at the March 2021 meeting of the APC:

- CD&T APC Drug Monitoring Recommendations – reviewed and updated.
- SGLT2 inhibitors Amputation risk - Northern Foot Care Network Recommendations
- Regional Gender Dysphoria Guidelines – reviewed & updated.

#### DECISION SUMMARY

- CD&T APC Patient Decision Aids Resource – review & updated.

The following shared care guidelines were presented to and approved at the March 2021 meeting of the APC:

- CD&T APC Dapsone Shared Care Guideline – new shared care guideline
- CD&T APC Riluzole Shared Care Guideline – review & updated
- Tees Ciclosporin Shared Care Guideline– reviewed & updated to include dermatology.

Other documents presented to and approved at the March 2021 meeting of the APC:

- CD&T APC Terms of Reference – updated.